SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Financial graph overlaid on stacks of co
Business
Biopharma’s Q3 Earnings Season Sees Mixed Results as Challenges Remain
With headwinds in the wider biotech sphere, the third quarter showed continuing vulnerabilities in the COVID space while the weight-loss drugs drove blockbuster sales.
November 8, 2023
 · 
5 min read
 · 
Tyler Patchen
Pictured: Gilead's headquarters in Silicon Valley/
Drug Development
Gilead, Arcus Anti-TIGIT Combo Gets Phase II Win in Upper GI Cancers
A combination of Gilead Sciences’ domvanalimab and Arcus Biosciences’ zimberelimab, along with chemo, has shown an “encouraging” overall response rate in a mid-stage study.
November 7, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: IPO concept art showing stacks of coins
Deals
Cargo Therapeutics Plans $315M IPO, Targets Cell Therapies for Cancer
The cell therapy-focused biotech will use most of the net proceeds from its initial public offering to fund Phase II clinical trials for its lead program, a novel CAR T-cell candidate.
November 7, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Person undergoing an eye exam
Drug Development
Kodiak Breathes New Life into Failed Eye Drug with Phase III Victory
Although Kodiak Sciences initially scrapped its development of tarcocimab tedromer after late-stage failures, new data has convinced the company to give the eye drug another shot.
November 6, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Bristol Myers Squibb office in California
Business
BMS Pays $100M Upfront for ADC from Korean Biotech Orum Therapeutics
After its deal with Tubulis in April 2023, Bristol Myers Squibb is continuing its antibody-drug conjugate buying spree by acquiring an asset from South Korea’s Orum Therapeutics.
November 6, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Regeneron logo on a light brown building
Business
Regeneron’s Eylea Sales Decline in Q3, Battle with Roche’s Vabysmo Heats Up
While Regeneron Pharmaceuticals reported better-than-expected third-quarter results, sales of the company’s lead drug Eylea declined amid increased competition.
November 3, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Facade of Moderna's building in Massachusetts
Business
Moderna Posts Q3 Loss, Takes $1.3B in Write-Downs on COVID-19 Shots
While Moderna’s total revenue for the third quarter beat analyst expectations, the company Thursday reported a loss as demand for its COVID vaccines declined.
November 2, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Merck building and sign in Silicon Valley
FDA
Merck’s Keytruda Plus Chemo Secures FDA Approval for Biliary Tract Cancer
The company’s blockbuster cancer drug continues to snap up FDA approvals, this time in treating biliary tract cancer in combination with cisplatin and gemcitabine. It’s the sixth indication in gastrointestinal cancers.
November 2, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Money growth/iStock, RomoloTavani
Business
VC Firm Bioluminescence Ventures Launches with $477M in Assets
The biotech venture capital firm, led by former Andreessen Horowitz senior partner Kouki Harasaki, emerged from stealth on Wednesday focused on investing in companies with first-in-class or best-in-class therapies.
November 1, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: GSK's office in Poznan, Poland/iStock, W
Business
GSK Inks $1B Deal Securing Rights to Arrowhead, J&J’s Hepatitis B Drug
The British biopharma and Arrowhead Pharmaceuticals have reached an agreement with J&J’s Janssen to transfer worldwide rights to develop and commercialize JNJ-3989 to GSK.
November 1, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Pfizer's signage at its world headquarters in New York
Business
Pfizer Continues COVID Cliff in Q3 with First Quarterly Loss Since 2019
Third-quarter revenues for antiviral treatment Paxlovid dropped 97% operationally compared with the prior-year period, while vaccine Comirnaty revenues declined 70% in the quarter.
October 31, 2023
 · 
2 min read
 · 
Tyler Patchen
Load More